Clozapine Withdrawal: Serotonergic or Dopaminergic Mechanisms?-Reply

Archives of General Psychiatry

Volumn 54, Issue 8, 1997, Pages 761-762

  Baldessarini, Ross J ^a   Tarazi, Frank I ^a   Kula, Nora S ^a   Gardner, David M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008579686     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830200095014     Document Type: Article

References (16)

1. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry. 1995;52:1071-1072.
2. Meltzer HY. Clozapine withdrawal: serotonergic or dopaminergic mechanisms? Arch Gen Psychiatry. 1997;54:760-761.
3. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology. 1995;120:365-368.
4. Kula NS, Baldessarini RJ, Kebabian JW, Neumeyer JL. S(+)-aporphines are not selective for human D3 dopamine receptors. Cell Mol Neurobiol. 1994;14:185-191.
5. Baldessarini RJ, Frankenburg FR. Clozapine, an atypical antipsychotic. N Engl J Med. 1991;324:746-754.
6. Kebabian JW, Tarazi FI, Kula NS, Baldessarini RJ. Compounds selective for dopamine receptor subtypes. Drug Discovery Today. In press.
7. Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature. 1993;365:441-145.
8. Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JR. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci. 1995;15:2186-2191.
9. Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev Psychiatry. 1996;3:301-325.
10. Baldessarini RJ. Dopamine receptors and clinical medicine. In: Neve RL, Neve KA, eds. The Dopamine Receptors. Totowa, NJ: Humana Press; 1997:457-498.
11. Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopament receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience. In press.
12. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Longterm effects of S( +)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolombic D4-like dopamine receptors. Neuropsychopharmacology. In press.
13. Campbell A, Yeghiayan SK, Baldessarini RJ, Neumeyer JL. Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic vs extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents. Psychopharmacology. 1991;103:323-329.
14. Campbell A, Baldessarini RJ, Neumeyer JL. Altered spontaeous behavior and responses to apomorphine in rats following pretreatment with S(+)aporphines or fluphenazine. Psychopharmacology. 1993;111:351-358.
15. Seeman P, Van Tol HHM. Dopamine D4 receptors bind inactive S(+ )aporphines, suggesting neuroleptic role: sulpiride not stereoselective. Eur J Pharmacol. 1993;233:173-174.
16. Lahti RA, Evans DL, Stratman NC, Figur LM. Dopamime D4 vs D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol. 1993;236:483-486.